Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties
- 1 October 1999
- journal article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 14 (10) , 1768-1778
- https://doi.org/10.1359/jbmr.1999.14.10.1768
Abstract
Bisphosphonates have emerged as a valuable treatment for postmenopausal osteoporosis. Bisphosphonate treatment is usually accompanied by a 3–6% gain in bone mineral density (BMD) during the first year of treatment and by a decrease in bone turnover. Despite low bone turnover, BMD continues to increase slowly beyond the first year of treatment. There is evidence that bisphosphonates not only increase bone volume but also enhance secondary mineralization. The present study was conducted to address this issue and to compare the effects of continuous and intermittent bisphosphonate therapy on static and dynamic parameters of bone structure, formation, and resorption and on mineral properties of bone. Sixty dogs were ovariohysterectomized (OHX) and 10 animals were sham-operated (Sham). Four months after surgery, OHX dogs were divided in six groups (n = 10 each). They received for 1 year ibandronate daily (5 out of 7 days) at a dose of 0, 0.8, 1.2, 4.1, and 14 μg/kg/day or intermittently (65 μg/kg/day, 2 weeks on, 11 weeks off). Sham dogs received vehicle daily. At month 4, there was a significant decrease in bone volume in OHX animals (p < 0.05). Doses of ibandronate ≥ 4.1 μg/kg/day stopped or completely reversed bone loss. Bone turnover (activation frequency) was significantly depressed in OHX dogs given ibandronate at the dose of 14 μg/kg/day. This was accompanied by significantly higher crystal size, a higher mineral-to-matrix ratio, and a more uniformly mineralized bone matrix than in control dogs. This finding lends support to the hypothesis that an increase in secondary mineralization plays a role in gain in BMD associated with bisphosphonate treatment. Moreover, intermittent and continuous therapies had a similar effect on bone volume. However, intermittent therapy was more sparing on bone turnover and bone mineral properties. Intermittent therapy could therefore represent an attractive alternative approach to continuous therapy.Keywords
This publication has 77 references indexed in Scilit:
- Continuous and cyclical clodronate therapies and bone density in postmenopausal bone lossPublished by Wolters Kluwer Health ,1999
- Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injectionJournal of Bone and Mineral Research, 1996
- Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosisBone, 1996
- Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapyJournal of Bone and Mineral Research, 1995
- Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral densityJournal of Bone and Mineral Research, 1993
- A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogsJournal of Bone and Mineral Research, 1993
- Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical propertiesCalcified Tissue International, 1993
- Effects of one-year cyclical treatment with clodronate on postmenopausal bone lossBone, 1993
- Skeletal fluorosis: Histomorphometric analysis of bone changes and bone fluoride content in 29 patientsBone, 1989
- A program package for quantitative analysis of histologic structure and remodeling dynamics of boneComputer Programs in Biomedicine, 1981